

## Trends of utilization and comparison between ams® vs. coloplast titan® inflatable penile prostheses (ipps) in italy – results from a national registry (insist-ed) (#144)

[Download \\*.ics](#)

**N. Schifano**<sup>1</sup>, G. Antonini<sup>1</sup>, C. Bettocchi<sup>1</sup>, F. Colombo<sup>1</sup>, G. Liguori<sup>1</sup>, S. Fiordelise<sup>1</sup>, A. Vitarelli<sup>1</sup>, M. Silvani<sup>1</sup>, M. Paradiso<sup>1</sup>, C. Ceruti<sup>1</sup>, F. Varvello<sup>1</sup>, F. Palumbo<sup>1</sup>, A. Avolio<sup>1</sup>, D. Pozza<sup>1</sup>, G. Franco<sup>1</sup>, M. Bitelli<sup>1</sup>, E. Conti<sup>1</sup>, E. Caraceni<sup>1</sup>, E. Pescatori<sup>1</sup>, A. Salonia<sup>1</sup>, A. Palmieri<sup>1</sup>, F. Deho<sup>1</sup>, P. Capogrosso<sup>1</sup>

<sup>1</sup> Italian Society of Andrology - SIA, Italy, Rome, Italy

### Objectives

Two manufacturers (AMS® and Coloplast®) provide the vast majority of the Inflatable penile prostheses (IPPs) available in the market. Data comparing the two IPP-brands are scant and little is known regarding the factors which may influence the implanters' preference when selecting the IPP-brand. We investigated these issues using the Italian multi-institutional national registry of penile prostheses (INSIST-ED).

### Methods

INSIST-ED registry, relating to patients implanted from 2014 to 2021, was analyzed. All data were prospectively recorded by 45 surgeons on a dedicated website ([www.registro.andrologiaitaliana.it](http://www.registro.andrologiaitaliana.it)) and revised by a data-manager. Patient's age, erectile dysfunction (ED) etiology, hospitalization type (private vs. public), and surgical volume were recorded. Logistic regression models were applied to explore the association between these features and the IPP-brand choice. Additionally, the complication rates and the quality of life and sexuality with penile prosthesis (QoLSPP) questionnaire scores were compared between who received an AMS® IPP vs. a Coloplast® one.

### Results

Overall, 1529 procedures were entered in the database from 2014 to 2021, with complete 1-yr follow-up QoLSPP questionnaires available for 207 patients. ED-aetiology related to organic ED, pelvic surgery/radiotherapy, and Peyronie's disease in 642 (42%), 566 (37%) and 306 (20%) patients, respectively. Overall, 900 (62%) AMS® and 378 (26%) Coloplast® IPPs were implanted, respectively. At logistic regression analysis, high-volume implanter were more likely to choose AMS (OR:1.1;95%CI1.07-1.13;p<0.0001)(Figure.1). Patients age, ED aetiology and hospital type were not associated with the use of one specific IPP-brand. Both complication rates and QoLSPP scores at follow-up were non-significantly different between AMS vs. Coloplast IPP-receivers.

### Conclusions

Patient's related features and hospitalization-type did not seem to influence the IPP-brand choice, whilst the implanters' own preference remained decisive to this respect, and especially so for high-volume implanters. Outcomes in terms of complication rates and satisfaction did not differ significantly between AMS vs. Coloplast IPP-receivers.

### Conflicts of Interest

No Conflicts of Interest to be declared




Figure 1